BOSTON, Massachusetts — August 5, 2025 — Leads & Copy — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) announced its financial results for the second quarter of 2025, alongside a corporate update. The company, which focuses on developing next-generation cancer therapeutics, anticipates full data from its Phase 1/2 dose expansion cohort by year-end 2025 and expects its cash runway to extend into the second quarter of 2026.
According to John Celebi, President and CEO, the second quarter marked a key transition for Sensei, shifting from early response-focused readouts to commercially relevant efficacy signals from the Phase 1/2 study of solnerstotug. Celebi noted the favorable safety profile of solnerstotug and its potential for better patient adherence and long-term outcomes when combined with cemiplimab.
Sensei is planning multiple Phase 2 studies across PD-(L)1 resistant tumor types, aiming to de-risk the advancement of solnerstotug and position it for multiple indications in the immunotherapy market. The final Phase 2 strategy will be influenced by the full dose expansion dataset expected later this year.
Solnerstotug, formerly SNS-101, is a conditionally active antibody targeting the VISTA immune checkpoint within the tumor microenvironment. A multi-center Phase 1/2 clinical trial is evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy as a monotherapy and in combination with Regeneron’s Libtayo® (cemiplimab) in patients with advanced solid tumors.
Corporate updates include the announcement of clinical data from the Phase 1/2 trial to be presented at the European Society for Medical Oncology (ESMO) Congress 2025 and Sensei regaining Nasdaq compliance after a reverse stock split.
Second quarter financial results show cash, cash equivalents, and marketable securities at $28.6 million as of June 30, 2025. Research and Development expenses were $2.5 million, and General and Administrative expenses were $2.7 million for the quarter. The net loss was $4.9 million.
Joyce Allaire, LifeSci Advisors, Jallaire@lifesciadvisors.com
Source: Sensei Biotherapeutics
